» Articles » PMID: 39707216

Targeting Programmed Cell Death in Diabetic Kidney Disease: from Molecular Mechanisms to Pharmacotherapy

Overview
Journal Mol Med
Publisher Biomed Central
Date 2024 Dec 20
PMID 39707216
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic kidney disease (DKD), one of the most prevalent microvascular complications of diabetes, arises from dysregulated glucose and lipid metabolism induced by hyperglycemia, resulting in the deterioration of renal cells such as podocytes and tubular epithelial cells. Programmed cell death (PCD), comprising apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis, represents a spectrum of cell demise processes intricately governed by genetic mechanisms in vivo. Under physiological conditions, PCD facilitates the turnover of cellular populations and serves as a protective mechanism to eliminate impaired podocytes or tubular epithelial cells, thereby preserving renal tissue homeostasis amidst hyperglycemic stress. However, existing research predominantly elucidates individual modes of cell death, neglecting the intricate interplay and mutual modulation observed among various forms of PCD. In this comprehensive review, we delineate the diverse regulatory mechanisms governing PCD and elucidate the intricate crosstalk dynamics among distinct PCD pathways. Furthermore, we review recent advancements in understanding the pathogenesis of PCD and explore their implications in DKD. Additionally, we explore the potential of natural products derived primarily from botanical sources as therapeutic agents, highlighting their multifaceted effects on modulating PCD crosstalk, thereby proposing novel strategies for DKD treatment.

Citing Articles

Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy.

Chen X, Wang M, Yan Z Diabetol Metab Syndr. 2025; 17(1):84.

PMID: 40051002 PMC: 11887226. DOI: 10.1186/s13098-025-01655-2.

References
1.
Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J . Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis. Sci Rep. 2019; 9(1):323. PMC: 6344540. DOI: 10.1038/s41598-018-36911-1. View

2.
Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X . Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. Molecules. 2019; 24(2). PMC: 6359411. DOI: 10.3390/molecules24020247. View

3.
Chen Y, Liu Q, Shan Z, Mi W, Zhao Y, Li M . Catalpol Ameliorates Podocyte Injury by Stabilizing Cytoskeleton and Enhancing Autophagy in Diabetic Nephropathy. Front Pharmacol. 2020; 10:1477. PMC: 6914850. DOI: 10.3389/fphar.2019.01477. View

4.
Wu X, Li Y, Zhang S, Zhou X . Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021; 11(7):3052-3059. PMC: 7847684. DOI: 10.7150/thno.54113. View

5.
Hu Q, Chen Y, Deng X, Li Y, Ma X, Zeng J . Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother. 2023; 159:114252. DOI: 10.1016/j.biopha.2023.114252. View